• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·US·Healthcare·LLY
Held by 4 Gurus
Share

Eli Lilly and Company Stocks

$ 1142.85Last Updated 02.10.2026

Issuer Rating

6/7
Performance

Favourable

Risk

Low

Recommendation

Buy

Market Cap

$ 1.09T

$ 1142.85
Key Takeaways

Risk factor

Negligible price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Excellent growth

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

In Guru Portfolios

Kenneth Griffin

Portfolio Weight (%)

0.8%

Change

+0.25%

Fund

CITADEL ADVISORS LLC

Cathie Wood

Portfolio Weight (%)

0.6%

Change

+0.51%

Fund

ARK Investment Management LLC

Bob Prince, Greg Jensen, Karen Karniol-Tambour

Portfolio Weight (%)

0.4%

Change

+0.14%

Fund

Bridgewater Associates

Manager
Fund
Portfolio Weight (%)
Change
Kenneth GriffinCITADEL ADVISORS LLC0.8%+0.25%
Cathie WoodARK Investment Management LLC0.6%+0.51%
Bob Prince, Greg Jensen, Karen Karniol-TambourBridgewater Associates0.4%+0.14%
Show more

Latest news

01.10.2026 14:44

Motley Fool: Novo could strengthen obesity pipeline by acquiring Kailera or Viking

29.09.2026 13:38

Novo licensed a Chinese weight-loss pill for $2.6 billion. What makes it unique?

28.09.2026 17:40

Motley Fool analyst calls Viking 'fantastic buy' for risk-tolerant investors

25.09.2026 15:20

Morning in New York: Inflation Expectations in the Spotlight

22.09.2026 21:39

Viking Therapeutics soars 31% intraday on upbeat data for its obesity shot

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Company Valuation

Greatly overvalued
1/7

From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks. Specifically, the stock is 'expensive' on P/E, overvalued

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Somewhat favourable
5/7

The average target price of LLY is 1273 and suggests 9.99% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendation

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

03.10.2026 18:01

Why are young investors more afraid of regret than of actual losses?

03.10.2026 16:01

Small caps last week: Iovance ups guidance, Accelevation IPO, Burry boosts SFM stake

03.10.2026 13:01

The Dollar Is Losing Ground to the Tenge, Anthropic Is Spooking Humanity, and Where Soccer Players Are Investing

03.10.2026 04:40

'It's over': Analysts discuss how AI threatens professional services, housing

03.10.2026 04:19

Boeing closer to approval of new 737 MAX 10 after software glitch deemed no concern

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026